loader image

Terms & Conditions/Privacy Policy

PRIVACY POLICY

This Privacy Policy explains how Eureka Therapeutics, Inc. (“Eureka”), handles Personal Information in connection with its interactions and communications, products, services, apps, and websites both online and offline (collectively, the “Services”). This Privacy Policy applies to all Personal Information received and processed by Eureka. Your access to and use of the Services is subject to this Privacy Policy and Eureka’s Terms of Use.

HOW WE COLLECT

We may collect Personal Data from you in a variety of ways, including, but not limited to:

  • Directly from you, (e.g., when you fill out a form, send us an inquiry, respond to a survey, register an account, or in connection with other activities, services, features, or resources we make available through our Services, including EurekaConnectMe)
  • Through our websites and mobile apps
  • Participation in clinical trials
  • From healthcare professionals
  • From contract research organizations and clinical trial investigators
  • From government agencies or public records
  • From third-party service providers, data brokers, or business partners
  • From industry and patient groups and associations

From time to time, we may use or augment the personal data we have about you with information obtained from other sources, such as public databases, social media platforms, and other third parties. For example, we may use such third-party information to confirm or verify licensure of healthcare professionals or to better understand your interests by associating demographic information with the information you have provided.

INFORMATION WE COLLECT

We may collect the following Personal Information

  • Contact information and preferences such as name, email address, mailing address, phone number, and emergency contact information
  • Biographical and demographic information, such as date of birth, age, gender, ethnicity, marital status, and sexual orientation
  • Health and medical information, such as information about physical and mental health conditions and diagnoses, treatments for medical conditions, genetic information, family medical history, and medications an individual may take, including the dosage, timing, and frequency of medication
  • Information we collect in connection with managing clinical trials, conducting research, providing patient support programs, distributing and marketing our products, managing compassionate use and expanded access programs
  • Financial information to complete a transaction or determine eligibility for patient assistance programs
  • Publicly available information
  • Inferences drawn from other Personal Data listed above, to create a profile reflecting your preferences, characteristics, behavior, attitudes, and abilities
  • Adverse event information
  • We may use the Personal Data we collect about you with information obtained from other sources, such as public databases, social media platforms, and other third parties
  • In limited circumstances and only with additional notice and consent, genetic information and biometric markers
  • Internet activity, such as your browsing history, your search history, and information on your interaction with our Services and advertisements
  • Username and password and any other information you provide in connection with establishing an account on our websites or mobile apps
  • Your photograph, social media handle, or digital or electronic signature
  • If you are a healthcare professional, we may also collect:
  • Professional credentials, educational and professional history, institutional and government affiliations, and information included on a resume or curriculum vitae education and work history (such as work experience, education, and languages spoken)
  • Information about the Eureka programs, products, and activities with which you have engaged
  • Details about our interactions with you, your prescribing of our products, and the agreements you have executed with us
  • Publicly available information related to your practice, such as license information, disciplinary history, prior litigation and regulatory proceedings, and other due diligence related information

We may use or augment the Personal Data we collect about you and your practice with information obtained from other sources, such as public databases, social media platforms, and other third parties. For example, we may use public information to confirm contact or financial information, to verify licensure of healthcare professionals, or to better understand your interests by associating demographic information with the information you have provided.

HOW WE USE PERSONAL DATA

Eureka processes your Personal Data for the following purposes:

  • Communicating with you about Eureka Services
  • Where you have requested participation in a clinical trial with Eureka or one of Eureka’s partners
  • Disease management, education, or decision support systems related to the use of Eureka investigational products and market product
  • Where you have requested support from Eureka, assisting you in the completion of your application, the assessment of your eligibility for any requested offering, the processing and maintenance of the offering, as well as any applicable renewal of such offering
  • Responding to your inquiries about applications, trials, and other offerings
  • Making proposals for future needs
  • Processing transactions through service providers
  • Conducting research and secondary research
  • Meeting legal, security, processing, and regulatory requirements
  • Protecting against fraud, or suspicious or other illegal activities
  • Compiling statistics for analysis of our sites and our business

WHY WE PROCESS PERSONAL DATA

Eureka processes Personal Data where it has a legal basis for doing so. Legal bases include:

  • The transfer or processing is in Eureka’s legitimate interest in providing you with access to our Services and programs
  • The transfer or processing is necessary for the performance of a contract between you, or your Provider, and Eureka (or one of its affiliates)
  • The transfer or processing is necessary for the performance of a contract, concluded in your interest, between Eureka (or one of its affiliates) and a third party
  • The transfer or processing is necessary, or legally required, on important public interest grounds, for the establishment, exercise, or defense of legal claims, or to protect your vital interests
  • The transfer or processing is required by applicable law

HOW WE SHARE PERSONAL DATA

Within our family of companies

In the normal course of performing services for our clients, Personal Data may be shared within Eureka and its affiliates for research and statistical purposes, drug safety and efficacy purposes, disease management, system administration and crime prevention or detection, or any purpose otherwise identified in this Privacy Policy.

With our Service Providers

We may retain other companies and individuals to perform services on our behalf and we may collaborate with other companies and individuals with respect to particular products or services. Examples of service providers include data analysis firms, customer service and support providers, email and SMS vendors, web hosting and development companies, and fulfillment companies. Providers also include our co-promote partners for products that we jointly develop and/or market with other companies. Some providers may collect Personal Data on our behalf.

In connection with Business Transactions

As we continue to develop our business, we might sell or buy assets. In such transactions, user information, including Personal Data, generally is one of the transferred business assets. Also, if either Eureka itself or substantially all of Eureka assets were acquired, your Personal Data may be one of the transferred assets. Therefore, we may disclose and/or transfer your Personal Data to a third party in these circumstances.

To comply with our legal obligations

Eureka reserves the right to disclose without your prior permission any Personal Data about you or your use of the Services if Eureka has a good faith belief that such action is necessary to: (a) protect and defend the rights, property, or safety of Eureka, employees, other users of the Services, or the public; (b) enforce the terms and conditions that apply to use of the Services; (c) as required by a legally valid request from a competent governmental authority and/or to comply with a judicial proceeding, court order, or legal process; or (d) respond to claims that any content violates the rights of third parties. We may also disclose Personal Data as we deem necessary to satisfy any applicable law, regulation, legal process, or governmental request.

We may also disclose aggregate or de-identified data that is not personally identifiable to third parties for any purpose.

Please note, Eureka does not sell Personal Data to third parties.

COOKIES AND OTHER TOOLS

Eureka websites and apps may collect information that could be potentially personally identifiable about your visits without you actively submitting such information. This information may be collected using various technologies, such as cookies and web beacons. Cookies are small text files that are transferred to your computer’s hard disk by a website. Web beacons (also referred to as GIFs, pixels, or internet tags) help Eureka understand how you navigate around the Eureka websites. As part of your use of the site, your internet browser automatically transmits to Eureka websites some of this unidentified information, such as the URL of the website you just visited and the browser version your computer is operating. Passive information collection technologies can make your use of Eureka websites easier by allowing Eureka to provide better service, customize Eureka websites based on consumer preferences, compile statistics, analyze trends, and otherwise administer and improve Eureka websites. You can prevent the storage of cookies by adjusting the settings on your browser, though certain features of Eureka websites may not work without use of passive information collection technologies. Information collected by these technologies cannot be used to identify you without additional information.

Some of Eureka’s business partners, with whom Eureka contracts to carry out the Services (e.g., website providers), may use their cookies on Eureka websites and apps. Although Eureka may not have direct access to or control over such cookies, this Privacy Policy governs the use of cookies by Eureka and such business partners on Eureka websites and apps. Eureka may also allow social media companies (e.g., Facebook) to put “widgets” on Eureka websites. These third-party tools may also be used to track you across websites. For example, so long as you are logged into Facebook, every time you land on a webpage that has a Facebook widget, Facebook will know you are on that webpage. Eureka does not control the privacy practices of these third parties.

Some internet browsers allow you to limit or disable the use of tracking technologies that collect unidentified information, such as a “Do Not Track” (“DNT”) setting. Currently, we do not respond to DNT signals.

SPECIAL PROGRAMS AND CLINICAL TRIALS

Eureka may offer apps, special programs, clinical trials, activities, events, or promotions (“Programs”) that have unique or additional specific terms, privacy notices, and/or consent forms that explain how any information you provide will be processed in connection with the Programs. Certain Programs may include coupons, discounts, or other financial incentives. Where required, we may provide additional terms. You should review the terms applicable to the Programs before interacting or participating in the Program.

CHILDREN

The Services Eureka provides are not intended to target children under the age of 13, and we do not knowingly collect information directly from children under this age through our websites or apps. We may handle the information of children in connection with certain programs, but only with the consent of a parent or legal guardian.

If you believe that a child of whom you are the parent or legal guardian has improperly provided us with Personal Data, please contact Eureka using one of the methods specified herein and Eureka will work with you to address this issue.

INTERNATIONAL DATA TRANSFERS

Eureka maintains servers and other storage facilities in the United States. Eureka may transfer Personal Data outside of its country of origin for the purposes, and in the manner, set out above; including for processing and storage by service providers and Affiliates in connection with such purposes. In all situations, Eureka takes reasonable steps to ensure that your privacy is protected. Such steps include, but are not limited to: implementing privacy, security, and contractual controls; as well as steps noted above, as required by applicable law.

To the extent that any Personal Data is sent out of an individual’s country, it is subject to the laws of the country in which it is held, and may be subject to disclosure to the governments, courts, or law enforcement or regulatory agencies of such other country, pursuant to the laws of such country.

Eureka endeavors to obtain assurances from its Service providers and Affiliates that they will safeguard Personal Data consistent with this Privacy Policy. An example of appropriate assurances that may be provided by Service providers and Affiliates includes a contractual obligation that they provide at least the same level of protection as is required by Eureka’s privacy principles set out in this Privacy Policy. Where Eureka has knowledge that a Service provider or Affiliate is using or disclosing Personal Data in a manner contrary to this Privacy Policy, Eureka will take appropriate steps to prevent or stop the use or disclosure.

CHOICE

Where Eureka relies on consent for the fair and lawful processing of Personal Data, the opportunity to consent will be provided prior to when the Personal Data in question is collected. Your consent may be given through your authorized representative such as a legal guardian, agent, or holder of a power of attorney. Where Eureka relies on consent, you will be entitled to withdraw that consent at any time.

DATA INTEGRITY, PURPOSE LIMITATION, AND RETENTION

Eureka will use Personal Data only in ways that are compatible with the purposes for which it was collected, or consented to by the individual. Eureka will have appropriate steps in place to ensure that Personal Data is relevant to its intended use, accurate, complete, and current. Eureka will only store Personal Data for as long as it is needed to fulfill the purposes for which it was collected, subject to applicable data retention periods imposed upon Eureka by applicable law. This may mean that your Personal Data is stored by Eureka for a number of years, depending on the purpose and need for that data to be processed.

YOUR RIGHTS

You may have certain rights and choices regarding our processing of our Personal Data. Depending on your jurisdiction, applicable law may entitle you to additional consumer rights, including the right to:

  • Know the categories and/or specific pieces of Personal Data collected about you, including whether your Personal Data is sold or disclosed, and with whom your Personal Data was shared
  • Access a copy of the Personal Data we retain about you
  • Request deletion of your Personal Data
  • Correct or amend your Personal Data
  • Object to certain uses of your Personal Data

We will verify your identity in connection with any requests regarding Personal Data to help ensure that we provide the information we maintain to the individuals to whom it pertains, and allow only those individuals or their authorized representatives to exercise rights with respect to that information. If you are an authorized agent making a request on behalf of a consumer, we may require and request additional information to verify that you are authorized to make that request.

Eureka may not be able to comply with a request where Personal Data has been destroyed, erased, or made anonymous in accordance with Eureka’s record retention obligations and practices. In the event that Eureka cannot provide an individual with access to his/her Personal Data, Eureka will provide the individual with an explanation, subject to any legal or regulatory restrictions.

To submit a request, please contact us using one the following options:

Through our web portal for residents of the US and other countries

To help us respond to your request, all communications to Eureka should include the and contact information (such as email address or phone number), and a detailed explanation of the request. In addition, communications related to Eureka websites should include, as applicable, the email address used for registration and the Eureka website address on which Personal Data was provided. Email requests to delete, amend, or correct Personal Data should include “Deletion Request” or “Amendment/Correction Request,” as applicable, in the subject line of the email. Eureka will endeavor to respond to all reasonable requests in a timely manner, and in any case, within any time limits prescribed by applicable local law. If you have questions or complaints regarding our Privacy Policy or practices, please contact us at privacy@eurekainc.com or at the mailing address provided above.

We will not restrict or deny you access to our Services because of choices and requests you make in connection with your Personal Data. Please note, certain choices may affect our ability to deliver the Services.

LINKS TO THIRD-PARTY WEBSITES

You may find advertising or other content on the Site that links to the sites and services of our partners, suppliers, advertisers, sponsors, licensors, and other third parties (“Third-Party Websites”). This Privacy Policy does not apply to the Third-Party Websites. We do not control the content or links that appear on these sites and are not responsible for the practices employed by websites linked to or from the Site. In addition, these sites or services, including their content and links, may be constantly changing. These sites and services may have their own privacy policies. Browsing and interaction on any other website, including websites which have a link to the Site, is subject to that website’s own terms and policies.

CHANGES TO EUREKA’S PRIVACY POLICY

Eureka has the discretion to update this Privacy Policy at any time. If Eureka changes its privacy practices, an updated version of this Privacy Policy will reflect those changes. Eureka will provide notice of such changes by updating the effective date listed on this Privacy Policy. We encourage you to frequently check this page for any changes to stay informed about how we are protecting the Personal Data we collect. It is your responsibility to review this Privacy Policy periodically and become aware of modifications. If you have an account through the Site or any Service we provide, we may provide notice of changes by emailing you at the email address provided to us in your account. Your continued interaction with Eureka, in the activities covered above, will be subject to the then-current Privacy Policy.

SECURITY

Eureka has implemented reasonable physical, technical, and managerial controls and safeguards to keep your Personal Data protected from unauthorized access, disclosure, alteration, and destruction. Such measures may include, but are not limited to: the encryption of communications, encryption of information while it is in storage, firewalls, access controls, separation of duties, and similar security protocols.

Access to Personal Data is limited to a restricted number of Eureka employees whose duties reasonably require such information, third parties with whom Eureka contracts to carry out business activities for Eureka, and certain companies with which Eureka may conduct joint programs. Eureka trains its employees on the importance of privacy and how to handle and manage Personal Data appropriately and securely.

Please note, the confidentiality of Personal Data transmitted over the internet cannot be guaranteed. Eureka urges you to exercise caution when transmitting Personal Data over the internet. Eureka cannot absolutely guarantee that unauthorized third parties will not gain access to your Personal Data; therefore, when submitting Personal Data to Eureka online, you must weigh both the benefits and the risks.

CONTACTING EUREKA

If you have any questions about this Privacy Policy, please contact us at . Alternatively, letters may be sent to the following address:

Eureka Therapeutics, Inc. Attn: Privacy 5858 Horton Street, Suite 170 Emeryville, CA 94608

All communications to Eureka should include the individual’s name and contact information (such as email address or phone number), and a detailed explanation of the request. Email requests to delete, amend, or correct Personal Data should include “Deletion Request” or “Amendment/Correction Request,” as applicable, in the subject line of the email. Eureka will endeavor to respond to all reasonable requests in a timely manner, and in any case, within any time limits prescribed by applicable local law.

image41

EUREKA THERAPEUTICS, ARTEMIS, and E-ALPHA are registered trademarks owned by Eureka Therapeutics, Inc.
© 2022 Eureka Therapeutics, Inc. All rights reserved

Facebook Twitter Linkedin

Randy W. Schekman, PhD

University of California, Berkeley

Dr. Randy W. Schekman is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute. He shared the 2013 Nobel Prize for Physiology or Medicine for work on cell membrane vesicle trafficking.

The discoveries from the Schekman lab has enabled the production of one third of the world’s supply of recombinant human insulin and one hundred percent of the world’s supply of recombinant hepatitis B vaccines. Dr. Schekman studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University.

His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the University of California, San Diego. At Berkeley, he developed a genetic and biochemical approach to the study of eukaryotic membrane traffic, and Schekman’s laboratory investigates the mechanism of membrane protein traffic in the secretory pathway in eukaryotic cells.

In addition to Nobel Prize, Dr. Schekman has received numerous honors and awards, including the Lewis S. Rosenstiel Award in basic biomedical science, the Gairdner International Award, the Amgen Award of the Protein Society, the Albert Lasker Award in Basic Medical Research and the Louisa Gross Horwitz Prize of Columbia University.

He is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, a Foreign Associate of the Accademia Nazionale dei Lincei, a Foreign Associate of the Royal Society of London and an Honorary Academician of the Academia Sinica.

Lewis T. "Rusty" Williams, MD, PhD

Walking Fish Therapeutics, Inc

Dr. Lewis T. Williams is the Co-Founder, Chairman and CEO of Walking Fish Therapeutics, Inc., a biotechnology company focused on developing B cell therapies.

Prior to Walking Fish, Dr. Williams founded and served as a director of Five Prime Therapeutics, Inc., a public biotechnology company, from January 2002 to January 2020, and served as its President and Chief Executive Officer from April 2011 to December 2017. Previously, Dr. Williams spent seven years at Chiron Corporation, a biopharmaceutical company, now known as Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer.

He also served on Chiron’s board of directors from 1999 to 2001. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco, and served as Director of the University’s Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease.

He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams was previously a member of the board of directors of COR Therapeutics, Inc., and Beckman Coulter, Inc., each of which was a public company during his service as a director.

He currently serves on the Boards of Protagonist Therapeutics, Neoleukin Therapeutics and Arcellx Therapeutics. Dr. Williams has also served as a venture partner of Quan Capital, LLP, a healthcare-focused venture capital firm, since October 2018. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.

David A. Scheinberg, MD, PhD

Memorial Sloan Kettering Cancer Center

Dr. Scheinberg is currently Vincent Astor Chair and Chairman, Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute; Chairman, Experimental Therapeutics Center, Memorial Sloan Kettering Cancer Center.

He is also Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSKCC. As a physician-scientist, Dr. Scheinberg specializes in the care of patients with leukemia. He investigates new therapeutic approaches to cancer, both in the hospital and in the laboratory.

The focus of his research is the discovery and development of novel, specific immunotherapeutic agents. Eight different therapeutic agents developed by Dr. Scheinberg’s laboratory have reached human clinical trials, which include the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, the first tumor specific fusion oncogene product vaccines, and antibodies to intracellular proteins.

Dr. Scheinberg has published more than 280 papers, chapters, or books in these fields. Dr. Scheinberg received his bachelor’s degree from Cornell University and his MD degree and PhD degree in pharmacology and experimental therapeutics from the Johns Hopkins University School of Medicine.

W. Michael Kavanaugh, MD

University of California, San Francisco

Dr. W. Michael Kavanaugh is the former Chief Scientific Officer and Head of Research and Non-Clinical Development of CytomX Therapeutics. He is a licensed physician Board-certified in Internal Medicine and Cardiovascular Disease and serves as Associate Clinical Professor of Medicine at the University of California, San Francisco and on the Scientific Advisory Boards of several companies.

Prior to CytomX, Dr. Kavanaugh was Senior Vice President and Chief Scientific Officer of Five Prime Therapeutics. Before Five Prime, Dr. Kavanaugh served as the Vice President of Novartis Vaccines & Diagnostics, Inc. and Executive Director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis as part of the company’s acquisition of the Chiron Corporation in 2006, where he held positions as Vice President and Head of Antibody and Protein Therapeutics Research.

Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute.

Stephan A. Grupp, MD, PhD

Children’s Hospital of Philadelphia (CHOP)

Stephan Grupp, MD PhD, is the Director of Translational Research for the Center for Childhood Cancer Research at Children’s Hospital of Philadelphia (CHOP), and the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania.

He is a member of the Division of Oncology, the Stem Cell Transplant group, and is Medical Director of the Stem Cell Laboratory. Dr. Grupp completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University.

He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of engineered cell therapies in high risk pediatric cancers. His primary laboratory interest is the molecular control of leukemic cell growth and the development of new cell therapy treatments for pediatric cancers.

Dr. Grupp is a reviewer for several journals and the author of over 120 peer- reviewed journal articles, as well as numerous abstracts and book chapters. He is also the national Chair for Stem Cell Transplantation for the Children’s Oncology Group. Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program. His PhD is in Immunology.

Yuman Fong, MD

City of Hope Medical Center

Dr. Yuman Fong is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.

He is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He was previously appointed to the faculty of the Memorial Sloan-Kettering Cancer Center, where he served on staff for over 20 years, and held the Murray F. Brennan Chair. He is best known clinically for his extensive work in the field of liver and pancreatic surgery–especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. Dr. Fong has also been active in biologic bench investigation.

His laboratory is focused in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.

He has co-authored over 800 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).

William S. Solari III

Director

Mr. Solari has served as a member of our board of directors since March 2018.

Mr. Solari has been a solo law practitioner through his professional corporation, Law Office of William S. Solari III, since February 2018.

Prior to working as a solo practitioner, he served as a partner at Jeffer Mangels Butler & Mitchell LLP, a law firm, from April 1990 through February 2018, where his practice focused on corporate, real estate law and U.S. and foreign income, gift, estate and GST tax.

Mr. Solari holds a B.A. in Economics and B.S.in Accounting from the University of California, Berkeley. He received a J.D. from the University of California, Hastings College of Law in 1977 and a LLM in tax from New York University School of Law in 1978.

Marvin Samson

Director

Mr. Samson has served as a member of our board of directors since August 2018. He founded and has served as the Chief Executive Officer of Samson Medical Technologies, L.L.C., a company specializing in injectable drug delivery systems and programs for hospital and alternate site pharmacists, since 1998.

Mr. Samson was also Chief Executive Officer and Chairman of the Board of Directors of Qualitest Pharmaceuticals Inc., a pharmaceutical company, from 2007 until its purchase by Endo Pharmaceuticals at the end of 2010. Prior to Qualitest Pharmaceuticals, he served as President, Chief Executive Officer and a member of the board of directors of SICOR, Inc., a pharmaceutical company previously listed on the Nasdaq, from 2001 until it was acquired by Teva Pharmaceutical Industries, Ltd., a pharmaceutical company, in 2004, after which he served as the Group Vice President of Worldwide Injectables of Teva until 2007.

Prior to that, Mr. Samson was the founder, President and Chief Executive Officer of Marsam Pharmaceuticals Inc. (NASDAQ: MSAM), a publicly held pharmaceutical company until its acquisition in 1995, from 1985 to 1998, and a founder, President and Chief Executive Officer of Elkins-Sinn, Inc. (now West-ward, a division of Hikma Pharmaceuticals), from 1967 through 1985.

Mr. Samson currently serves on the boards of directors of public company Antares Pharma, Inc. (Nasdaq: ATRS), as well as privately held companies Flynn Pharma Ltd. and NanoPass Technologies Ltd. He also serves as Chairman of the Board of Directors of privately held company Heritage Pharmaceuticals, Inc. Mr. Samson previously served on the boards of directors of Circassia Pharmaceuticals plc, a specialty biopharmaceutical company public in the United Kingdom, as well as privately held companies JHP Pharmaceuticals, LLC (prior to its acquisition by Par Pharmaceutical Companies Inc.), Emcure Pharmaceuticals, Ltd. and Baxa Corporation (prior to its acquisition by Baxter International).

Mr. Samson is also Chairman of the Board of Trustees of the University of the Sciences in Philadelphia and a Trustee of two non-profit organizations, Virtua Health System and The Franklin Institute. Mr. Samson holds five U.S. patents pertaining to pharmaceutical manufacturing. He holds a B.S. in Chemistry from Temple University.

Chih-Kai Cheng

Director

Mr. Cheng is co-founder and General Partner of Acorn Pacific Ventures. Prior to co-founding Acorn Pacific Ventures in 2015, he was the co-founder of Harbinger Venture Capital.

Mr. Cheng also serves on the boards of directors of [Crown BioScience] and Primax Electronics Corp., both listed on the Taiwan Stock Exchange, and the following privately held companies: Gaatu Inc. H3 Platform, Inc., B Current Impact Investment and Social Enterprise Insights. He previously served on the boards of directors of the following privately held companies: Quintic Corporation, Cardiva, General Photonics, Applied Optoelectronics, Inc. (prior to its initial public offering), Envivio, Inc. (prior to its initial public offering), Centrality Inc. His previous investments include Actrans (acquired by SSTI), Arques (acquired by California Micro Devices), Celestry (acquired by Cadence), Centrality (acquired by SiRF), Paxera (acquired by NeoPhotonics), Plaxo (acquired by Comcast), Synnex (listed in NYSE), and Tasman Networks (acquired by Nortel).

Prior to founding Harbinger Venture in 2000 with the anchor investment from MiTAC/Synnex Group, Mr. Cheng was Senior Vice President of Product Marketing at Synnex (NYSE:SNX). During his 8-year tenure with Synnex, he held various management responsibilities including product line management, engineering, manufacturing operations, new business development, and corporate development. In 2007, Mr. Cheng was Chairman of the Monte Jade Science and Technology Association, an association for Chinese technology and business professionals in the Bay Area. He also writes regularly for several magazines on business trends and philosophy.

Mr. Cheng received his M.S. from National Chiao-Tung University, Taiwan, and B.S.in Physics from National Tsing-Hua University, Taiwan.

Jacqueline Northcut

Director

Ms. Northcut has served as a member of our board of directors since September 2018. Since January 2018, Ms. Northcut has served as a co-founder and the President, Treasurer and Secretary of Oleon Therapeutics, Inc., a company recently formed for the purpose of in-licensing therapeutics-based assets.

From December 2003 until October 2015, Ms. Northcut served as President and Chief Executive Officer of BioHouston, a non-profit organization founded by Houston, Texas area academic/research institutions to assist in the commercialization efforts of development stage life science and biotechnology companies.

From July 2010 through October 2015, Ms. Northcut also served as the founder and Chief Executive Officer of Texas BioAlliance, an organization created to further assist with development efforts of biotechnology and medical device companies in the state of Texas. In these capacities, she organized the Texas Life Science Forum and the Texas Life Science CEO Summit, helping connect biotechnology chief executive officers with funding, technical, regulatory and other resources.

Ms. Northcut was previously a Partner in the international accounting firm of Arthur Andersen & Co., where she worked from 1984 to 2002. From May 2016 to July 2017, Ms. Northcut served on the board of directors of Moleculin Biotech, Inc. (Nasdaq: MBRX), a publicly traded preclinical pharmaceutical company.

She also previously served on the board of Chrysalis BioTherapeutics, a privately held early-stage biopharmaceutical company, from May 2016 through February 2018. She holds a B.B.S. from Harding University.

Sandy Chau

Director

Mr. Chau has served as a member of our board of directors since our inception in February 2006. Mr. Chau has been actively engaged in private venture capital investment, and the ownership, development and management of real estate in the United States and Greater China for over 30 years.

Mr. Chau has served as the managing member of Desert Spring Biotech Capital, LLC and Suma Ventures LLC, each an investment entity, since February 2006 and November 2011, respectively. Mr. Chau has also served on the investment committee of Acorn Campus China Fund I, LP, a venture capital fund, since August 2012, and prior to that, held various roles as an advisor or member of various funds in the Acorn group of investment funds since 2006.

As a private venture capital investor, Mr. Chau has played a significant role in the early sourcing, financing and development of Crown Bioscience, Inc. (acquired by JSR Life Sciences), Waterstone Pharmaceuticals, Inc., Osel, Inc. and Autekbio, Inc., among other companies. In the information technology sector, Mr. Chau was an early investor in Gigamon Inc. (acquired by Elliot Management), Fortinet, Inc., Accela, Inc. (acquired by Berkshire Partners), SINA Corporation, Telenav, Inc., Achievo Corporation (acquired by Beyondsoft) and Innolight, among other companies. He holds a B.S. in Chemical Engineering from the University of California, Berkeley and an MBA from California State University, East Bay.

Our board of directors believes that Mr. Chau’s expertise and experience in the venture capital industry and his educational background provide him with the qualifications and skills to serve on our board of directors.

Michael Cannon

Director

Mr. Cannon has served as a member of our board of directors since January 2016. Since May 2005, Mr. Cannon has been a Co-Owner of Cannon Venture No. 2 LP, a venture capital company.

Mr. Cannon has over forty years of experience in the pharmaceutical industry. Previously, he worked at SICOR Inc., a Swiss-Italian API manufacturing company, in a variety of positions in manufacturing, quality and regulatory affairs, before transitioning to business development. Mr. Cannon was a member of the team that orchestrated the merger of SICOR with Gensia of San Diego in 1997 and after the merger he served as Chief Scientific Officer.

He then served as a member of SICOR’s board and president of the biotech division until the company was sold to Teva in 2004. Mr. Cannon currently serves on the board of directors of two public companies, Athenex, Inc. (Nasdaq: ATNX) and Moleculin Biotech, Inc. (Nasdaq: MBRX), the privately owned BioSentinel Pharmacueticals, Inc. and three two other privately held companies. Mr. Cannon holds a B.S. in Chemistry from Fordham College.

Our board of directors believes that Mr. Cannon’s expertise and experience in the life sciences industry, experience as a director of other public companies in our industry and his educational background provide him with the qualifications and skills to serve on our board of directors.

Hanzhong Li, PhD

Senior VP of Corporate Strategy

Mr. Li has served as our Senior Vice President of Corporate Development since February 2019.

He is responsible for business and corporate development. Dr. Li has over twenty years of experience in the biopharmaceutical industry and in finance on Wall Street. Prior to Eureka, he served as CFO Ascentage Pharma Group, a biotech company. From 2010 to 2017, Dr. Li worked in Strategic Marketing at Bayer Pharmaceuticals, responsible for Strategy and Portfolio Management and Commercial Development. Before Bayer, Dr. Li worked for Morgan Stanley, Suntrust Robinson Humphrey and Stanford Financial Group.

Dr. Li holds a PhD degree in Pharmacology from Boston University School of Medicine and an MBA. degree in Finance from University of California at Los Angeles.

Victor Shum

General Counsel & CBO

Mr. Shum has served as our Chief Business Officer since August 2018, our General Counsel since March 2016 and our Secretary since December 2016. Prior to that, he was a partner in the corporate group at Jeffer Mangels Butler & Mitchell LLP.

Mr. Shum has over 18 years of experience advising public and private companies on corporate and finance matters, including securities offerings, mergers, acquisitions and strategic transactions, corporate governance and securities law compliance.

Before his legal career, Mr. Shum was an engineer at the Mobil Oil Corporation. Mr. Shum holds a BS in Materials Science and Engineering from the University of California, Berkeley and a JD from the University of California, Hastings College of the Law.

Vivien Chan, PhD

COO

Vivien Chan, Ph.D. has served as our Chief Operating Officer since August 2018 and as our Vice President of Portfolio Management from October 2014 to August 2018.

Prior to joining our company, Dr. Chan served in multiple roles at Novartis AG, most recently as Director of Bioinformatics in Oncology at the Novartis Institutes for BioMedical Research, or NIBR, from June 2010 to May 2014, where she led the team that provided data analysis, data capture and integration and bioinformatics analysis for oncology project teams, target ID and validation, Translational Medicine and Pharmacology within NIBR Oncology.

Dr. Chan also previously served as a Research Scientist in oncology target discovery at Chiron Corporation prior to its acquisition by Novartis in April 2006. Dr. Chan completed her post-doctoral training at the University of California, San Francisco. She holds a B.A. in Chemistry from the College of Wooster and a Ph.D. in Biochemistry from the University of California, San Francisco, where she was also a Howard Hughes Medical Institute Pre-Doctoral Fellow.

Cheng Liu, PhD

Founder, President & CEO

Dr. Cheng Liu is the Founder, President and CEO of Eureka Therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis).

With over 20 years of experience in the field, he holds more than 500 patents and published patent applications of which over 100 patents have issued worldwide and has authored numerous peer-reviewed papers on cancer immunotherapy.

He is the inventor of multiple first-in-class, clinical-stage cancer drugs against various tumor targets, including drugs targeting CSF1 for the treatment of bone metastasis, BCMA for multiple myeloma, and AFP and GPC3 for liver cancer. In 2007, he was awarded Special U.S. Congressional Recognition for his contributions to improving human health.

He is the editor of the book “Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development”. Dr. Liu received his B.S. in Cell Biology and Genetics from Peking University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.